AtlasGEN Novel Drug Designer: Design Clinical Success Into New Drug Discovery from Day One
Author: Szczepan Baran, VeriSIM Life Chief Scientific Officer.
Introduction
Designing a new drug molecule to fight diseases and pathogens is extremely difficult, time consuming, and expensive. Even when a disease’s pathway is clearly understood and a target identified, finding a drug compound that is selective, potent, safe, and with favorable physiological exposure in humans requires significant scientific trial and error, even with the help of computers. The underlying challenge is that drug discovery and design is typically aimed mostly at potency and not at the overall translational success! Accordingly, while the number of registered new drug candidates has increased 72%, the relative proportion of approved drugs from big pharma has fallen from 76% to 25%.1 More importantly, the failure rate of novel candidates in clinical trials remains unchanged at 90%.2
With the overall drug development cost more than $150 Billion for big pharma3, a mere 10% improvement in the clinical translation success rate represents a multi-billion dollar opportunity for the industry and patients in need.
Download '.pdf' Format of the whitepaper.
